Magy Abdelwahab
Research Subjects
Research Interests
Magy Abdelwahab has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mahmood Shams
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Ali Dabbagh
Department of Anesthesiology, School of Medicine, Anesthesiology Research Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Alieh Fazeli
School of Paramedical Sciences, Shiraz University of Medical Sciences
1 shared publication - Alieh Fazeli
School of Paramedical Sciences, Shiraz University of Medical Sciences
1 shared publication - Andre Balzekiene
International Gaucher Alliance, Vilnius, Lithuania
1 shared publication - Beata Kieć-Wilk
Unit of Rare Metabolic Diseases, Department of Pathophysiology, Jagiellonian University Medical College, 31-121 Krakow, Poland
1 shared publication
Latest Publications
- Open Access
- 20 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Exploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions
Background: Gaucher disease is a rare lysosomal storage disorder caused by insufficient activity of the enzyme β-glucocerebrosidase. This leads to the accumulation of fatty deposits in cells and tissues and damages multiple organ systems. Diagnosing Gaucher disease often involves a prolonged and challenging “diagnostic odyssey”. The International Gaucher Alliance (IGA) conducted a survey among individuals living with Gaucher disease, including patients, families, and caregivers, to investigate diagnostic challenges. Distributed primarily in English language, with a Spanish translation for relevant IGA members, the survey was completed by 142 respondents from 40 different countries between November 2024 and February 2025. The study aims to guide future efforts to promote timely diagnosis, access to expert management, and treatment before irreversible damage occurs. Early diagnosis also brings emotional and practical benefits, including informed family planning and support networks. Results: The survey revealed that diagnostic delays remain prevalent, with 58% of respondents waiting more than a year for diagnosis. Key contributors to delays included low awareness among physicians and inadequate communication between medical specialties. Common “red flag” symptoms identified in guidelines were often linked to eventual diagnosis, highlighting the need to educate healthcare professionals, especially those likely to encounter patients but not consider Gaucher disease (e.g., internal medicine specialists and gastroenterologists). Notably, 17% of respondents were not made aware of the genetic nature of Gaucher disease when they were diagnosed, potentially missing opportunities to identify affected relatives or influence family planning. Respondents suggested that increased awareness among healthcare professionals, expanded access to newborn screening, and greater availability of genetic and enzymatic testing could significantly accelerate the process. Conclusions: As well as continuing to engage in education and awareness activities for specialists that commonly diagnose Gaucher, targeted awareness campaigns for secondary care clinicians that do not commonly diagnose Gaucher, but are regularly seen in the journey to diagnosis could reduce diagnostic delays. Providing lay-friendly resources to help specialists explain genetic inheritance to newly diagnosed patients may enhance early family diagnoses. Country-specific surveys to understand local diagnostic experiences could shape tailored interventions. Lastly, advocacy efforts to address access barriers, should amplify patient voices and prioritise community needs.
- 20 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessExploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions
Background: Gaucher disease is a rare lysosomal storage disorder caused by insufficient activity of the enzyme β-glucocerebrosidase. This leads to the accumulation of fatty deposits in cells and tissues and damages multiple organ systems. Diagnosing Gaucher disease often involves a prolonged and challenging “diagnostic odyssey”. The International Gaucher Alliance (IGA) conducted a survey among individuals living with Gaucher disease, including patients, families, and caregivers, to investigate diagnostic challenges. Distributed primarily in English language, with a Spanish translation for relevant IGA members, the survey was completed by 142 respondents from 40 different countries between November 2024 and February 2025. The study aims to guide future efforts to promote timely diagnosis, access to expert management, and treatment before irreversible damage occurs. Early diagnosis also brings emotional and practical benefits, including informed family planning and support networks. Results: The survey revealed that diagnostic delays remain prevalent, with 58% of respondents waiting more than a year for diagnosis. Key contributors to delays included low awareness among physicians and inadequate communication between medical specialties. Common “red flag” symptoms identified in guidelines were often linked to eventual diagnosis, highlighting the need to educate healthcare professionals, especially those likely to encounter patients but not consider Gaucher disease (e.g., internal medicine specialists and gastroenterologists). Notably, 17% of respondents were not made aware of the genetic nature of Gaucher disease when they were diagnosed, potentially missing opportunities to identify affected relatives or influence family planning. Respondents suggested that increased awareness among healthcare professionals, expanded access to newborn screening, and greater availability of genetic and enzymatic testing could significantly accelerate the process. Conclusions: As well as continuing to engage in education and awareness activities for specialists that commonly diagnose Gaucher, targeted awareness campaigns for secondary care clinicians that do not commonly diagnose Gaucher, but are regularly seen in the journey to diagnosis could reduce diagnostic delays. Providing lay-friendly resources to help specialists explain genetic inheritance to newly diagnosed patients may enhance early family diagnoses. Country-specific surveys to understand local diagnostic experiences could shape tailored interventions. Lastly, advocacy efforts to address access barriers, should amplify patient voices and prioritise community needs.
- 29 June 2025
- Published by Springer Nature
- p. 147-164
Laboratory Diagnosis of Congenital Tissue Factor Pathway Inhibitor
- 29 June 2025
- Published by Springer Nature
- p. 147-164
Laboratory Diagnosis of Congenital Tissue Factor Pathway Inhibitor
- 29 June 2025
- Published by Springer Nature
- p. 187-230
Laboratory Diagnosis of Less CommonAcquired and Congenital Thrombophilic Risk Factors
- 29 June 2025
- Published by Springer Nature
- p. 187-230
Laboratory Diagnosis of Less CommonAcquired and Congenital Thrombophilic Risk Factors
- 29 June 2025
- Published by Springer Nature
- p. 173-185
Laboratory Diagnosis of Combined Inherited/Genetic Thrombophilia
- 29 June 2025
- Published by Springer Nature
- p. 173-185
Laboratory Diagnosis of Combined Inherited/Genetic Thrombophilia
- Open Access
- 27 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 842
Home Enzyme Replacement Therapy in Gaucher Disease: A Review
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients’ quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
- 27 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 842
Open AccessHome Enzyme Replacement Therapy in Gaucher Disease: A Review
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients’ quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
- Open Access
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 3 (3) , e158
Previously unrecognized behavioral phenotype in Gaucher disease type 3
Objective: To provide a comprehensive description of abnormal behaviors in patients with Gaucher disease type 3 (GD3) and relate these behaviors to demographic, neurodevelopmental, and neurologic characteristics. Methods: Thirty-four Egyptian patients with GD3 (mean age of 7.9 years) were enrolled in the study. They were selected based on parent report and/or physician observation of one or more abnormal behaviors documented in 2 settings and by 2 different individuals and/or by video recording. Behaviors were grouped into 4 categories: Crying/Withdrawal, Impatience/Overactivity, Anger/Aggression, and Repetitive Acts. Baseline and follow-up 6–12 monthly neurologic evaluations included IQ assessment and an EEG. All patients were receiving enzyme replacement therapy (30–60 IU/kg every 2 weeks) and were followed for periods of 3–10 years. Results: Supranuclear palsy of horizontal gaze, and of both horizontal and vertical gaze, bulbar symptoms, seizures, convergent strabismus, abnormal gait, and neck retroflexion were present in 97.1%, 50%, 55.9%, 29.4%, 29.4%, 20.6%, and 4.4% of patients, respectively. The most abnormal behavioral features were excessive anger (88.2%) and aggression (64.7%), and both were significantly higher in males. Anger/Aggression scores were highly correlated with IQ but not with either EEG/Seizure status or neurologic signs. Conclusions: We describe behavioral problems with a unique pattern of excessive anger and aggression in patients with GD3. Defining these components using quantitative behavioral scoring methods holds promise to provide a marker of neurologic disease progression and severity.
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 3 (3) , e158
Open AccessPreviously unrecognized behavioral phenotype in Gaucher disease type 3
Objective: To provide a comprehensive description of abnormal behaviors in patients with Gaucher disease type 3 (GD3) and relate these behaviors to demographic, neurodevelopmental, and neurologic characteristics. Methods: Thirty-four Egyptian patients with GD3 (mean age of 7.9 years) were enrolled in the study. They were selected based on parent report and/or physician observation of one or more abnormal behaviors documented in 2 settings and by 2 different individuals and/or by video recording. Behaviors were grouped into 4 categories: Crying/Withdrawal, Impatience/Overactivity, Anger/Aggression, and Repetitive Acts. Baseline and follow-up 6–12 monthly neurologic evaluations included IQ assessment and an EEG. All patients were receiving enzyme replacement therapy (30–60 IU/kg every 2 weeks) and were followed for periods of 3–10 years. Results: Supranuclear palsy of horizontal gaze, and of both horizontal and vertical gaze, bulbar symptoms, seizures, convergent strabismus, abnormal gait, and neck retroflexion were present in 97.1%, 50%, 55.9%, 29.4%, 29.4%, 20.6%, and 4.4% of patients, respectively. The most abnormal behavioral features were excessive anger (88.2%) and aggression (64.7%), and both were significantly higher in males. Anger/Aggression scores were highly correlated with IQ but not with either EEG/Seizure status or neurologic signs. Conclusions: We describe behavioral problems with a unique pattern of excessive anger and aggression in patients with GD3. Defining these components using quantitative behavioral scoring methods holds promise to provide a marker of neurologic disease progression and severity.
- Open Access
- 1 April 2016
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 2 (2) , e55
Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt
Objective: To describe the long-term follow-up and distinct phenotype of a large cohort of patients with Gaucher disease type 3 on enzyme replacement therapy (ERT) in Egypt. Methods: A prospective cohort study of 78 patients on ERT who were followed for up to 9 years with yearly evaluations that included EEG and cognitive testing. Results: Of the patients, 73% were homozygous for the L444P GBA1 mutation; all but 7 were neurologically symptomatic. Supranuclear gaze palsy with variable but stable cognitive function was present in 91% of patients. Convergent strabismus and bulbar dysfunction were noted in 22% and 37%, respectively. Features of oppositional defiant disorder were present in 54% of patients. Twenty-three patients (30%) developed seizures while on ERT for 1–9 years. Of those, 12 patients (15%) died suddenly and unexpectedly at a mean age of 6.7 ± 5.0 years (range 1.5–18). Sudden death was usually associated with a seizure disorder or a terminal seizure, but 7 of 12 patients had a preceding normal EEG. An additional 11% had background slowing or epileptogenic activity on EEG without clinical seizures. There were 3 familial cases of sudden unexpected death. Conclusions: Despite having the most common GBA1 genotype known to be associated with neuronopathic Gaucher disease, patients with Gaucher disease type 3 in Egypt have a phenotype and a clinical outcome on ERT that are very different from those observed in other populations. Identifying putative modifying genes of this ethnic group is likely to lead to better therapy for neuronopathic Gaucher disease generally.
- 1 April 2016
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 2 (2) , e55
Open AccessLong-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt
Objective: To describe the long-term follow-up and distinct phenotype of a large cohort of patients with Gaucher disease type 3 on enzyme replacement therapy (ERT) in Egypt. Methods: A prospective cohort study of 78 patients on ERT who were followed for up to 9 years with yearly evaluations that included EEG and cognitive testing. Results: Of the patients, 73% were homozygous for the L444P GBA1 mutation; all but 7 were neurologically symptomatic. Supranuclear gaze palsy with variable but stable cognitive function was present in 91% of patients. Convergent strabismus and bulbar dysfunction were noted in 22% and 37%, respectively. Features of oppositional defiant disorder were present in 54% of patients. Twenty-three patients (30%) developed seizures while on ERT for 1–9 years. Of those, 12 patients (15%) died suddenly and unexpectedly at a mean age of 6.7 ± 5.0 years (range 1.5–18). Sudden death was usually associated with a seizure disorder or a terminal seizure, but 7 of 12 patients had a preceding normal EEG. An additional 11% had background slowing or epileptogenic activity on EEG without clinical seizures. There were 3 familial cases of sudden unexpected death. Conclusions: Despite having the most common GBA1 genotype known to be associated with neuronopathic Gaucher disease, patients with Gaucher disease type 3 in Egypt have a phenotype and a clinical outcome on ERT that are very different from those observed in other populations. Identifying putative modifying genes of this ethnic group is likely to lead to better therapy for neuronopathic Gaucher disease generally.
- Open Access
- 1 January 2013
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 33 (1) , 81-2
Reply
- 1 January 2013
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 33 (1) , 81-2
Open AccessReply
- 30 July 2012
- Published by Wiley in Haemophilia
- Vol. 18 (5) , e386-e388
Rare coagulation disorders: a study of 70 cases in the Egyptian population
- 30 July 2012
- Published by Wiley in Haemophilia
- Vol. 18 (5) , e386-e388
Rare coagulation disorders: a study of 70 cases in the Egyptian population
- Open Access
- 1 March 2012
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 32 (2) , 200-202
Prevalence of hepatitis C virus infection and human immunodeficiency virus in a cohort of Egyptian hemophiliac children
The risk of blood-borne infections, especially hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection still remains in developing countries among children receiving blood products as hemophiliacs, but the risk is not known in Egypt. The objective of this study was to detect the prevalence of HCV and HIV infection among hemophiliac children to know the magnitude of the problem and determine potential risk factors. This was a cross-sectional study conducted on 100 hemophiliac children that assessed the liver clinically and by laboratory tests. All children were screened for HCV and HIV antibodies by enzyme-linked immunosorbent assay. Those with positive HCV antibody titre were tested by polymerase chain reaction (HCV-PCR). Forty were positive for HCV antibodies with 19 children (47.5%) HCV-PCR positive as well. The mean age, average frequency of bleeds/year, dose of replacement therapy/year and alanine aminotransferase (ALT) levels were significantly high in HCV-antibody and PCR positive patients as compared to HCV antibody and PCR negative ones. None of our patients had clinical evidence of hepatic involvement or was co-infected with HIV. HIV infection does not appear to be a current health problem in Egyptian hemophiliac children though the prevalence of HCV infection is still high.
- 1 March 2012
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 32 (2) , 200-202
Open AccessPrevalence of hepatitis C virus infection and human immunodeficiency virus in a cohort of Egyptian hemophiliac children
The risk of blood-borne infections, especially hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection still remains in developing countries among children receiving blood products as hemophiliacs, but the risk is not known in Egypt. The objective of this study was to detect the prevalence of HCV and HIV infection among hemophiliac children to know the magnitude of the problem and determine potential risk factors. This was a cross-sectional study conducted on 100 hemophiliac children that assessed the liver clinically and by laboratory tests. All children were screened for HCV and HIV antibodies by enzyme-linked immunosorbent assay. Those with positive HCV antibody titre were tested by polymerase chain reaction (HCV-PCR). Forty were positive for HCV antibodies with 19 children (47.5%) HCV-PCR positive as well. The mean age, average frequency of bleeds/year, dose of replacement therapy/year and alanine aminotransferase (ALT) levels were significantly high in HCV-antibody and PCR positive patients as compared to HCV antibody and PCR negative ones. None of our patients had clinical evidence of hepatic involvement or was co-infected with HIV. HIV infection does not appear to be a current health problem in Egyptian hemophiliac children though the prevalence of HCV infection is still high.